Material Event (Form 8-K)

As previously disclosed, on April 19, 2026, Sila Realty Trust, Inc., a Maryland corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sunshine Ultimate Parent LLC, a Delaware limited liability company ("Parent"), and Sunshine Holding REIT LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, on the terms and subject to the conditions set forth therein, the Company will merge with and into Merger Sub with Merger Sub surviving the merger (the "Surviving Entity" and such merger transaction, the "Merger"). Upon completion of the Merger, the Surviving Entity will be owned and controlled by Parent.

In connection with the Merger, the Company filed with the Securities and Exchange Commission (the "SEC") a preliminary proxy statement on Schedule 14A on May 5, 2026 (the "Preliminary Proxy Statement"), and a definitive proxy statement on Schedule 14A on May 22, 2026 (the "Definitive Proxy Statement"), in each case, with respect to a special meeting of the Company's stockholders (the "Special Meeting"), which will be held on June 26, 2026 at 9:00 a.m., Eastern Time, in a virtual format by live webcast, to act on, among others, a proposal to approve the transactions contemplated by the Merger Agreement, as disclosed in the Definitive Proxy Statement.

As of June 16, 2026, the Company is aware of two (2) complaints that have been filed as individual actions in connection with the Merger by purported stockholders of the Company against the Company and the individual members of the Company's board of directors. The complaints are captioned as follows: (i) Thompson v. Sila Realty Trust, Inc. et al, Index No. 653296/2026 (N.Y. Sup. Ct. N.Y. Cnty. Jun. 2, 2026) and (ii) Grant v. Sila Realty Trust, Inc. et al, Index. No. 653217/2026 (N.Y. Sup. Ct. N.Y. Cnty. Jun. 1, 2026) (collectively, the "Complaints"). The Complaints seek to enjoin the defendants from proceeding with the Merger unless the defendants disclose certain purportedly material information alleged to have been omitted from the Preliminary Proxy Statement and/or the Definitive Proxy Statement and rescission of the Merger and/or damages if the Merger is consummated. In addition to the Complaints, as of June 16, 2026, the Company has received fifteen (15) demand letters from law firms claiming to represent purported Company stockholders, which also generally allege disclosure deficiencies in the Preliminary Proxy Statement and/or the Definitive Proxy Statement (collectively, the "Demand Letters" and, together with the Complaints, the "Matters").

The Company and the other defendants named in the Matters deny all allegations in the Matters and believe that the Matters are without merit and that no supplemental disclosure to the Preliminary Proxy Statement and/or the Definitive Proxy Statement was or is required under any applicable law, rule or regulation. However, solely to minimize the burden and expense of potential litigation, avoid nuisance and potential delay or disruption to the Merger and provide additional information to the Company's stockholders, the Company has determined to voluntarily supplement the Definitive Proxy Statement with the below disclosures. The Company believes that the disclosures in the Preliminary Proxy Statement and the Definitive Proxy Statement comply fully with applicable law and nothing in the supplemental disclosures will be deemed an admission of the legal necessity or materiality under applicable law of any of the disclosures set forth herein or of the legal merit of the legal proceedings described in the Definitive Proxy Statement. It is possible that additional, similar demand letters or complaints may be received or filed or the Matters may be amended. The Company does not intend to announce the receipt or filing of each additional, similar demand letter, complaint or any amended complaint.

SUPPLEMENTAL DISCLOSURES TO THE DEFINITIVE PROXY STATEMENT

These following supplemental disclosures should be read in connection with the Definitive Proxy Statement, which should be read in its entirety. The inclusion in this supplement to the Definitive Proxy Statement of certain information should not be regarded as an indication that any of the Company or its affiliates, officers, directors or other representatives, or any other recipient of this information, considered, or now considers, it to be material, and such information should not be relied upon as such. To the extent that information herein differs from or updates information contained in the Definitive Proxy Statement, the information contained herein supersedes or supplements the information contained in the Definitive Proxy Statement. The information contained herein speaks only as of the date of this Current Report on Form 8-K, unless the information indicates another date applies. Capitalized terms used but not defined herein have the meanings set forth in the Definitive Proxy Statement, unless otherwise defined below. All page references in the information below are references to pages in the Definitive Proxy Statement. For clarity, new text within restated paragraphs (other than tables and related footnotes) from the Definitive Proxy Statement is highlighted with bold, underlined text, and deleted text within restated paragraphs from the Definitive Proxy Statement is highlighted with strikethrough text.

Selected Publicly Traded Companies Analysis. BofA Securities reviewed publicly available financial and stock market information for the Company and the following five publicly traded healthcare REITs, selected based on BofA Securities' professional judgment and experience:

BofA Securities also reviewed publicly available financial and stock market information for the following five publicly traded net lease REITs, selected based on BofA Securities' professional judgment and experience:

(c)

The seventh paragraph on page 42 is amended and restated as follows:

Selected Precedent Transactions Analysis. BofA Securities reviewed, to the extent publicly available, financial information relating to the following four selected transactions involving healthcare REITs, selected based on BofA Securities' professional judgment and experience:

BofA Securities also reviewed, to the extent publicly available, financial information relating to the following seven selected transactions involving net lease REITs, selected based on BofA Securities' professional judgment and experience:

BofA Securities reviewed transaction values, calculated as the (i) enterprise values implied for each target company, based on the consideration payable in the applicable selected transaction, as a multiple of the respective target company's one-year forward estimated Adjusted EBITDA and (ii) equity values implied for each target company, based on the consideration payable in the applicable selected transaction, as a multiple of the target company's one-year forward estimated AFFO. BofA Securities then applied a range of one-year forward Adjusted EBITDA multiples of 11.5x to 15.5x and one-year forward AFFO multiples of 10.5x to 14.5x, derived by BofA Securities from the selected transactions based on its professional judgment and experience, to the Company's calendar year 2026 estimated Adjusted EBITDA and AFFO, as applicable. Estimated financial data of the selected transactions were based on publicly available information and research analyst estimates at the time of announcement of the relevant transaction. Estimated financial data of the Company were based on the Company management forecasts. This analysis indicated the following approximate implied per share equity value reference ranges for the Company, as compared to the Merger Consideration.

Discounted Cash Flow Analysis. BofA Securities performed a discounted cash flow analysis of the Company to calculate the estimated present value of the standalone unlevered, after-tax free cash flows that the Company was forecasted to generate during the Company's fiscal years 2026 through 2030 based on the Company management forecasts. BofA Securities calculated terminal values for the Company by applying an Adjusted EBITDA exit multiple range of 12.0x to 15.0x, based on BofA Securities' professional judgment and experience, to the estimated Adjusted EBITDA for the terminal year, which were calculated, at the Company's direction, by applying a growth rate of 2.0%, based on BofA Securities' professional judgment and experience, to the Company's estimated fiscal year 2030 Adjusted EBITDA of $168 million. The cash flows and terminal values were then discounted to present value as of December 31, 2025, assuming a mid-year convention for cash flows, using discount rates ranging from 7.8% to 8.7%, reflecting an estimate of the Company's weighted average cost of capital, as estimated by BofA Securities based on its professional judgment and experience. This analysis indicated the following approximate implied per share equity value reference ranges for the Company, as compared to the Merger Consideration.

On January 20, 2026, BofA Securities began contacting various third parties, including REITs, strategic real estate companies and financial sponsors, to gauge interest in a potential transaction involving the Company. Between January 20, 2026 and mid-March 2026, BofA Securities contacted 81 potentially interested third-party buyers. BofA Securities shared the form of nondisclosure agreement with each potential buyer that expressed an interest in receiving more information regarding a potential transaction with the Company, which non-disclosure agreement contained, among other provisions, a standstill provision, an employee non-solicitation provision, and a 24-month term. From January 20, 2026 through March 13, 2026, the Company negotiated nondisclosure agreements with approximately 43 third parties and entered into nondisclosure agreements with 31 third parties. None of the nondisclosure agreements contained 'don't ask, don't waive' provisions. Each party that executed a nondisclosure agreement with the Company was given access to certain diligence materials in a confidential virtual data room (the "Round I Data Room").

Party D submitted a revised preliminary indication of interest for an acquisition of all the outstanding Company Common Stock for a purchase price of $29.94 per share in cash (the "Revised Party D Proposal" and, together with the Blue Owl Proposal, the Consortium A Proposal, the Party C Proposal, the Party E Proposal, the Party F Proposal, the Party G Proposal and the Party H Proposal, the "Preliminary Proposals"). All other material terms of the Revised Party D Proposal aligned with the Original Party D Proposal. None of the Preliminary Proposals included any discussions or proposals regarding post-closing employment arrangements or the participation in the equity of the surviving company for any members of the Board or the Company's executive officers.

In addition, between March 9, 2026 and March 16, 2026, the Company received preliminary indications of interest from four additional bidders that submitted proposals to acquire a portion of the Company's assets, which proposals did not conform to the Company's February 17, 2026 instructions to bidders to provide a proposed per share purchase price for the acquisition of the Company. None of these four additional proposals included any discussions or proposals regarding post-closing employment arrangements or the participation in the equity of the surviving company for any members of the Board or the Company's executive officers.

Later in the day on April 15, 2026, Consortium B submitted a final letter of interest indicating, among other items, a proposal to acquire all outstanding Company Common Stock for $26.00 per share in cash (the "Consortium B Final Proposal"). The Consortium B Final Proposal did not include any discussions or proposals regarding post-closing employment arrangements or the participation in the equity of the surviving company for any members of the Board or the Company's executive officers.

Later in the evening on April 15, 2026, Blue Owl submitted a final letter of interest indicating, among other items, a proposal to acquire all outstanding Company Common Stock for $30.38 per share in cash (the "Blue Owl Final Proposal"). The Blue Owl Final Proposal provided that the Company could continue the payment of its regular quarterly dividends, not to exceed $0.40 per share. Additionally, Blue Owl requested an exclusivity period with the Company for a period of 10 days. The Blue Owl Final Proposal did not include any discussions or proposals regarding post-closing employment arrangements or the participation in the equity of the surviving company for any members of the Board or the Company's executive officers.

Substantially concurrently with the foregoing telephone call between Mr. Seton and Consortium A, representatives of BofA Securities received a letter from Consortium A that indicated that Consortium A was continuing to work on a proposal for the Company but would not be submitting a proposal until April 20, 2026. Consortium A never submitted a final proposal for the Company.